$CRBU

Caribou Biosciences, Inc.

CIK:0001619856|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenue ($ from related party for the three months ended xxx, respectively)	$ 1,499	$ 2,667	$ 3,896	$ 5,020
Operating expenses:
Research and development	18,942	27,692	39,553	63,223
General and administrative	7,896	10,403	15,962	20,138
Asset, Impairment Loss	0	12,150	0	12,150
Total operating expenses	26,838	50,245	55,515	95,511
Loss from operations	(25,339)	(47,578)	(51,619)	(90,491)
Other income (expense)
Impairment Of Equity Method Investment	0	(9,158)	0	(9,158)
Other income, net	1,057	2,638	2,252	5,560
Total other income (expense)	1,057	(6,520)	2,252	(3,598)
Net loss	(24,282)	(54,098)	(49,367)	(94,089)
Other comprehensive loss
Net unrealized loss on available-for-sale marketable securities, net of tax	(48)	(127)	(174)	(215)
Net comprehensive loss	$ (24,330)	$ (54,225)	$ (49,541)	$ (94,304)
Net loss per share, basic (in dollars per share)	$ (0.24)	$ (0.58)	$ (0.50)	$ (1.01)
Net loss per share, diluted (in dollars per share)	$ (0.24)	$ (0.58)	$ (0.50)	$ (1.01)
Weighted-average common shares outstanding, basic (in shares)	100,985,698	93,028,698	98,437,862	92,855,060
Weighted-average common shares outstanding, diluted (in shares)	100,985,698	93,028,698	98,437,862	92,855,060

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (49,367)	$ (94,089)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,274	2,332
Gain (Loss) on Disposition of Assets	0	(25)
Asset, Impairment Loss	0	12,150
Change in fair value of equity securities	0	(4)
Stock-based compensation expense	4,834	7,011
Change in fair value of the MSKCC success payments liability	0	(785)
Impairment Of Equity Method Investment	0	9,158
Accretion of discounts on investments in marketable securities, net	(313)	(745)
Non-cash lease expense	636	965
Changes in operating assets and liabilities:
Accounts receivable	(134)	194
Contract assets	403	405
Other receivables	769	(129)
Prepaid expenses and other current assets	574	811
Other assets	13	1,896
Accounts payable	(2,643)	774
Accrued expenses and other current liabilities	(3,390)	(2,413)
Deferred revenue, current and long-term	(1,855)	(1,845)
Operating lease liabilities	(572)	(635)
Non Cash Consideration For Licensing And Collaboration Revenue	0	(9)
Net cash used in operating activities	(49,771)	(64,983)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sales and maturities of marketable securities	85,587	122,628
Purchases of marketable securities	(42,587)	(47,751)
Purchases of property and equipment	(73)	(1,460)
Net cash provided by investing activities	42,927	73,417
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options	21	6
Proceeds from issuances of common stock under ESPP	468	468
Proceeds from issuances of common stock related to ATM, net of offering expenses	20,143	0
Net cash provided by financing activities	20,632	474
NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	13,788	8,908
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — BEGINNING OF PERIOD	12,406	16,339
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — END OF PERIOD	26,194	25,247
RECONCILIATION OF CASH, CASH EQUIVALENTS, AND RESTRICTED CASH
Cash and cash equivalents	26,194	25,201
Restricted cash	0	46
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH ON THE BALANCE SHEET	26,194	25,247
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Purchases of property and equipment included in accounts payable and accrued expenses	$ 0	$ 67

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
CURRENT ASSETS
Cash and cash equivalents	$ 26,194	$ 12,360
Marketable securities, short-term	86,120	126,980
Accounts receivable	203	69
Contract assets	603	1,006
Other Receivables, Net, Current	1,135	1,904
Prepaid expenses and other current assets	2,340	2,913
Total current assets	116,595	145,232
NON-CURRENT ASSETS
Marketable securities, long-term	1,504	3,505
Property and equipment, net	5,499	6,760
Operating lease, right of use assets	17,035	17,670
Other assets	2,141	2,200
TOTAL ASSETS	142,774	175,367
CURRENT LIABILITIES
Accounts payable	3,080	5,783
Accrued expenses and other current liabilities	13,145	16,535
Operating lease liabilities, current	1,377	1,201
Deferred revenue	372	1,895
Total current liabilities	17,974	25,414
LONG-TERM LIABILITIES
Deferred revenue, net of current portion	1,420	1,752
Operating lease liabilities, non-current	25,278	26,026
Total liabilities	44,672	53,192
COMMITMENTS AND CONTINGENCIES (Note 8)
STOCKHOLDERS’ EQUITY
Common stock, par value $0.0001 per share, 300,000,000 shares authorized as of June 30, 2026, and December 31, 2025; 105,995,653 and 95,143,690 shares issued and outstanding as of June 30, 2026, and December 31, 2025, respectively	11	9
Additional paid-in-capital	744,044	718,578
Accumulated other comprehensive (loss) income	(71)	103
Accumulated deficit	(645,882)	(596,515)
Total stockholders’ equity	98,102	122,175
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 142,774	$ 175,367